Background. Gene-based vaccine delivery is an important strategy in the development of a preventive vaccine for acquired immunodeficiency syndrome (AIDS). Vaccine Research Center (VRC) 004 is the first phase 1 doseescalation study of a multiclade HIV-1 DNA vaccine.
antigens. A joint meeting between the Vaccine Research Center (VRC) (National Institute of Allergy and Infectious Diseases [NIAID] , National Institutes of Health [NIH] , Department of Health and Human Services) and the Joint United Nations Programme on HIV/AIDS concluded that testing of multiclade candidate vaccines is a high international scientific priority [2] . Sequences encoding gene products from 3 high-incident HIV subtypes were used to produce the candidate vaccine evaluated in the present study [3, 4] . Multiple antigens expressed by the vaccine elicit responses against multiple epitopes and may diminish the chances for immune escape.
Delivering antigens by DNA plasmids has potential advantages over other vector delivery systems, notably the lack of antivector immunity. Despite examples of vaccine-induced protection in mice and nonhuman primates [5, 6] , DNA immunization has shown limited immunogenicity in humans [7] [8] [9] [10] [11] . Here, we report the findings from a phase 1 clinical trial of a multigene, multiclade HIV-1 DNA candidate vaccine and dem-onstrate the induction of HIV-1-specific T cell and antibody responses.
METHODS
Study design. VRC 004 (NIH 03-I-0022) was conducted at the NIH by the VRC. It was a randomized, double-blind, placebo-controlled phase 1 dose-escalation study. A randomization sequence was obtained by use of computer-generated random numbers, and blocking ensured balance across groups. The study was opened to accrual on 13 November 2002 and was unblinded on 24 September 2004. Vaccine safety and immunogenicity were the primary and secondary objectives, respectively. Eligibility criteria included HIV-seronegative status; age 18-40 years; being amenable to HIV risk-reduction counseling; having good general health as determined by medical history, physical exam, and laboratory tests; and having no prior exposure to investigational HIV vaccines. Fifty subjects were randomized to receive placebo ( ) or vaccine at doses of 2 n p 10 mg ( ), 4 mg ( ), or 8 mg ( ). Safety reviews n p 5 n p 20 n p 15 were conducted in both the 2-mg and 4-mg groups (5 vaccine recipients and 2 placebo recipients) before randomizing the remaining 36 subjects to the 4-mg, 8-mg, or placebo groups. The NIAID Intramural Data and Safety Monitoring Board conducted safety reviews for the dose escalation from 4 to 8 mg as well as at 6-month intervals throughout the study. Injections (1 mL/injection) were administered on day 0 and at weeks 4 and 8. Arms were alternated for sequential vaccinations, except for the delivery of the 8-mg dose of vaccine, which required 1-mL injections of 4 mg into both arms. Evaluations included laboratory tests, physical assessments by clinicians, and selfassessment for local and systemic symptoms recorded on 7-day diary cards. Adverse events were graded for severity by use of a preapproved table that incorporated a 5-point scale and were coded by use of Medical Dictionary for Regulatory Activities terminology. HIV testing was done by RNA polymerase chain reaction (Roche Amplicor HIV-1 Monitor Test) and ELISA (Abbott HIVAB HIV-1/HIV-2 rDNA); Western blotting (Genetic Systems HIV Western blot kit; BioRad Laboratories; performed at the Mayo Laboratory, Rochester, MN) was done if ELISA results were positive. The social impact of participating in an HIV vaccine study was monitored.
Vaccine. The vaccine, VRC-HIVDNA009-00-VP, was developed by the VRC and is manufactured by Vical; it is composed of 4 closed, circular, DNA plasmids at a concentration of either 2 mg/mL or 4 mg/mL (figure 1). The plasmid expressing clade B HIV-1 Gag-Pol-Nef fusion polyproteins comprised 50% of the vaccine by weight. The plasmids expressing Env glycoprotein from clades A, B, and C each comprised 16.67% of the vaccine by weight. Before formulation of the vaccine product, expression levels of individual plasmids were assessed semiquantitatively by Western blot densitometry and were compared with standards run under the same conditions. Preclinical testing demonstrated the product to have an acceptable safety profile [13, 14] .
The placebo used was calcium and magnesium free (Vical). All injections were administered with a needle-free injection device into the deltoid muscle by use of a Biojector 2000 (Bioject).
Antibodies. Unconjugated mouse anti-human CD28, unconjugated mouse anti-human CD49d, allophycocyanin (APC)-conjugated mouse anti-human CD3, fluorescein isothiocyanate (FITC)-conjugated mouse anti-human CD8, peridinin chlorophyll protein-conjugated mouse anti-human CD4, and a mixture of phycoerythrin (PE)-conjugated mouse anti-human interferon (IFN)-g and interleukin (IL)-2 monoclonal antibodies were obtained from Becton Dickinson Immunocytometry Systems (BDIS). Independent evaluation of IFN-g and IL-2 required CD4cy5.5PE and CD8QDot655 conjugation (for details, see http://drmr.com/abcon) in combination with CD3cy7APC, IFN-g FITC, and IL-2 APC (BDIS). To determine the optimum concentration for staining, reagents were independently titrated.
Cell preparation. Peripheral-blood mononuclear cells (PBMCs) were prepared by Ficoll-Paque density gradient centrifugation (Pharmacia). PBMCs were frozen in heat-inactivated fetal calf serum containing 10% dimethylsulfoxide in a Forma CryoMed cell freezer. Cells were stored at Ϫ180ЊC. Immunogenicity assays were performed on thawed specimens; average viability was 195%.
Peptides. Peptides (15 aa in length, overlapping by 11 aa, and corresponding to the vaccine inserts) were synthesized at 185% purity as confirmed by high-performance liquid chromatography. Peptides were pooled for each protein (EnvA, EnvB, EnvC, Gag, Nef, and Pol [2 pools]) and were used at a final concentration of 2.5 mg/mL.
Cell stimulation. PBMCs (10 6 ) in 200 mL of R-10 medium (RPMI 1640 supplemented with 10% heat-inactivated fetal bovine serum, 100 U/mL penicillin G, 100 mg/mL streptomycin sulfate, and 1.7 mmol/L sodium glutamate) were incubated with costimulatory anti-CD28 and anti-CD49d monoclonal antibodies (1 mg/mL each) each and with each peptide (2.5 mg/ mL) in 96-well V-bottom plates. Cells incubated with costimulatory antibodies only were included in every experiment, to control for spontaneous production of cytokine and activation of cells before addition of peptides. Staphylococcal enterotoxin B (SEB; 1 mg/mL; Sigma-Aldrich) was used as a positive control for lymphocyte activation. Cultures were incubated at 37ЊC in a 5% CO 2 incubator for 6 h in the presence of brefeldin A (10 mg/mL; Sigma).
Intracellular cytokine staining (ICS) assays. ICS assays for IFN-g and/or IL-2 in CD4 + and CD8 + T cells were performed after stimulation with overlapping peptide pools representing the vaccine antigens. PBMCs were permeabilized for 7 min in Figure 1 . Schematic of the DNA vaccine design. Four separate DNA plasmids were produced by inserting individual HIV-1 gene constructs into the pVR1012 backbone under the control of the cytomegalovirus (CMV) immediate-early (IE) promoter, followed by the bovine growth hormone polyadenylation (bGH poly A) sequence [3, 12] . The synthetic gag gene is from the clade B strain HXB2 (GenBank accession no. K03455), the synthetic pol gene (pol/ h) is from the clade B strain NL4-3 (GenBank accession no. M19921), and the synthetic nef gene (nef/h) is from the clade B strain PV22 (GenBank accession no. M19921). Mutations (indicated by Xs), including the deletion of the carboxy-terminus of Gag (indicated by the triangle), were introduced in the protease and reverse-transcriptase genes to prevent processing of the pol gene products and to reduce the potential for functional enzymatic activity. This resulted in a fusion protein that directly reads through the frame shift in Gag (F2) through Pol and into Nef. This gene product is not able to assemble or produce pseudoparticles. To create synthetic gp145, versions of the envelope genes were truncated immediately downstream of the transmembrane domain of gp41. In each construct, the cleavage site and fusion peptide at the junction of gp120 and gp41 were deleted, and a portion of the interspace between the 2 heptad-repeat regions in gp41 was deleted. The Env gene products are primarily cell associated rather than secreted. The EnvA sequence is from 92rw020 (CCR5 tropic; GenBank accession no. U08794), the EnvB sequence is from HXB2 (CXCR4 tropic; GenBank accession no. K03455), and the EnvC sequence is from 97ZA012 (CCR5 tropic; GenBank accession no. AF286227). HR1-HR2, heptad-repeat regions in gp41; IN, integrase; NC, nucleocapsid; PR, protease; V1-V5, variable regions in envelope.
200 mL of a solution containing 100 mL of Tween 20 (Sigma), 160 mL of deionized water, and 40 mL of 10ϫ FACS-Lyse solution (BDIS) at room temperature; were washed twice in cold Dulbecco's PBS containing 1% fetal bovine serum and 0.02% sodium azide (FACS buffer); and were stained with directly conjugated anti-human antibodies for 20 min on ice. Stained cells were then immediately washed twice with cold FACS buffer. The cells were resuspended in Dulbecco's PBS containing 1% paraformaldehyde (Electron Microscopy Systems) and then stored at 4ЊC until analysis.
Flow-cytometric analysis. Flow-cytometric analysis was performed on a FACSCalibur flow cytometer (BDIS). Between 50,000 and 250,000 events, gated on small lymphocytes, were acquired and analyzed using FlowJo software (version 8.1; Tree Star Software). The same cytokine, CD4, and CD8 gates were used for the entire trial.
Enzyme-linked immunospot (ELISpot) assays. ELISpot assays were performed using a commercially available ELISpot kit (BD Biosciences) [3] . PBMCs were stimulated overnight at 37ЊC in triplicate wells at a density of cells/well for all 5 2 ϫ 10 stimulations other than SEB, which was conducted at 4 5 ϫ 10 cells/well. After incubation, cells were lysed, and the wells were washed and incubated for 2 h at room temperature in the presence of biotinylated IFN-g detection antibodies. Subsequently, the wells were incubated with an avidin-horseradish peroxidase solution for 1 h at room temperature, followed by incubation for 20 min with 3-amino-9-ethylcarbazole substrate solution. The plate was air-dried for a minimum of 2 h before spot quantitation on a CTL ELISpot image analyzer (Cellular Technology). Results are expressed as the mean number of spotforming cells per 10 6 PBMCs. Measurement of antibody responses. Research ELISAs were performed to delineate the antibody response to individual viral antigens encoded in the vaccine. End-point titers of antibodies directed against HIV antigens were determined using 96-well Immulon 2 plates (Dynex Technologies) coated with a preparation of purified recombinant HIV proteins, in accordance with methods adapted from those described elsewhere [15] . Analysis by immunoprecipitation followed by Western blotting (IP-Western blotting) was performed as described else- are not included in this table. All other subjects ( ) remained polymerase n p 48 chain reaction (PCR) negative throughout the study. Aside from the results for the 2 HIV-infected subjects, the Western blot results were all in the indeterminate category. A positive Western blot result required a band at p24 in addition to a band for at least 1 of the envelope glycoproteins (gp41, gp120, or gp160). If there were bands present that did not meet the positivity criteria, the result was reported as indeterminate.
where [3] . Screening for HIV-1 neutralization activity was performed on 1:5 dilutions of serum in a flow cytometry-based assay that measured levels of intracellular p24 after a single round of HIV-1 infection of PBMCs, as described elsewhere [16] .
Statistical methods. T cell data are summarized by rates of positive response to the individual peptide pools and exact, 2-sided 95% confidence intervals (CIs). Positivity criteria consisted of a statistical hypothesis test for a difference between stimulated and unstimulated wells and a minimal level of response requirement, as described elsewhere [17] . The minimum threshold for background-corrected positive-response percentage was 0.0241% for CD4 + T cells and 0.0445% for CD8 + T cells for the ICS assays and was 50 sfc/10 6 PBMCs for the ELISpot assays. SAS (version 8.2; SAS Institute) and Splus (version 6.0; Insightful) were used for analyses.
RESULTS

Subject population.
Subjects had a mean age of 29 years, and 60% were men. Vaccine and placebo recipients had similar demographic characteristics (table 1) . Vaccinations were completed in 9 of the 10 subjects in the placebo group, in 5 of the 5 subjects in the 2-mg group, in 20 of the 20 subjects in the 4-mg group, and in 14 of the 15 subjects in the 8-mg group. All subjects completed 52 weeks of follow-up.
Vaccine safety. Three adverse events that were possibly related to vaccination were notable. They included grade 3 asymptomatic neutropenia with onset 27 days after the third vaccination (4-mg group), grade 3 urticaria with onset 4 days after the third vaccination (4-mg group), and grade 2 maculopapular rash with onset 27 days after the second vaccination (8-mg group); the last subject did not receive the third vaccination. All resolved without sequelae and had alternative explanations. Vaccinations were well tolerated, and there were no episodes of severe reactogenicity (table 1). The placebo group reported an incidence of pain similar to that of the vaccine groups but reported less induration and erythema; there was no suggestion of a dose effect.
Fourteen (40% [95% CI, 24%-58%]) of the 35 subjects who received 4-or 8-mg injections had vaccine-induced positive diagnostic ELISA results, and 7 (20% [95% CI, 8%-37%]) had indeterminate Western blot results (table 2) . Most commonly, the first positive ELISA result occurred at week 12, with a return to background levels by week 52; there were 6 subjects with a positive ELISA result at week 52.
Vaccine-specific antibody responses. Env-specific antibody responses were observed by IP-Western blotting in postimmunization serum only ( figure 2A ). EnvA-, EnvB-, and EnvCspecific antibody responses were observed ( figure 2B ). The frequency of antibody responses increased with the dose; there were none observed at the 2-mg dose, 8 (40%) of 20 at the 4-mg dose, and 12 (80%) of 15 at the 8-mg dose ( figure 2C, black  bars) . figure 2D ). Vaccineinduced HIV antibody was observed in only 1 subject by 1 test method in the 2-mg group. Serum neutralizing activity against the MN strain of HIV-1 was !80% in all subjects, indicating that no substantial neutralizing activity was present.
Vaccine-induced T cell responses. T cell responses were detected by both ELISpot and ICS assay and were most frequent to Env antigens. The ICS cytokine gating strategy is shown by a representative analysis at week 12, which demonstrates responses to EnvA, EnvB, and EnvC peptide pools in CD4 + and CD8 + T cells ( figure 3 ). EnvA peptides elicited responses of the greatest magnitude ( figure 4A and 4B ). Responses were detected after 2 immunizations in most vaccine recipients, with the highest response rate observed at week 12 (4 weeks after the third immunization) ( figure 5 and table 3 ). The median magnitude of the T cell response as measured by both ELISpot and ICS assay generally peaked at week 10 or 12 for all peptide pools and persisted through week 52 ( figure 4A ). For EnvA, week 12 As measured by ELISpot assay, there was a statistically significant difference in the number of positive EnvA, EnvB, and EnvC responses in vaccine recipients ( ) at week 12, comn p 39 pared with that at baseline ( , , and , P ! .0001 P ! .0001 P p .001 respectively, exact McNemar tests). Gag, Pol, and Nef responses among vaccine recipients were not significantly different between baseline and week 12.
Positive CD4 + T cell responses as measured by ICS assay for at least 1 of the vaccine-specific antigens were detected in 39 (97.5%) of the 40 vaccine recipients for at least 1 time point by week 12. At week 12, compared with that at baseline, there was a statistically significant difference ( for all, exact P р .0001 McNemar tests) in the number of vaccine recipients with a CD4 + T cell response to EnvA, EnvB, and EnvC but not to Gag, Pol, or Nef.
Positive CD8 + T cell responses as measured by ICS assay for peptides representing at least 1 of the vaccine antigens were detected in 16 (40%) of the 40 vaccine recipients by week 12. At week 12, compared with that at baseline, there was a statistically significant difference ( and , re-P p .002 P p .0313 spectively, exact McNemar tests) in the number of vaccine recipients with a CD8 + T cell response to EnvA and EnvB but not to EnvC; no vaccine recipients had a CD8 + T cell response to Gag, Pol, or Nef.
Although there was a trend toward a greater magnitude (figure 4) and frequency (figure 5) of T cell responses in recipients of the 4-or 8-mg dose than in the recipients of the 2-mg dose, this difference was not statistically significant at week 12. The pattern of responses as measured by ELISpot assay throughout the study was consistent with the pattern as measured by ICS assay. The frequency and magnitude were greatest for EnvA and EnvB, with weaker responses to EnvC, few responses to Gag, and no responses to Nef or Pol ( figure 5 ).
Once T cell responses were detected, they remained detectable in the majority of subjects for the 52 weeks of follow-up (figures 4A and 5 and table 3 ). The functional properties of the vaccine-induced T cell response changed qualitatively over time. A representative T cell cytokine-production profile for IL-2 and IFN-g at week 12 is shown in figure 6A . The CD4 + and CD8 + T cell subsets contain cells that make IL-2 only, IFNg only, or both. At week 12, CD4 + T cells tended to make IL-2 only or in combination with IFN-g, whereas the great majority of CD8 + T cells typically produced IFN-g only (figure 6A). At week 52, both T cell subsets tended to have a higher frequency of IL-2-producing cells and a lower frequency of IFN-g-producing cells (figure 6B).
DISCUSSION
This 4-plasmid HIV-1 DNA candidate vaccine was assessed as safe and well tolerated in healthy uninfected adults. Importantly, DNA immunization induced both HIV-1-specific antibody and T cell responses to the Env proteins of the 3 major subtypes of HIV-1. We have shown that DNA as a gene-delivery platform for HIV-1 vaccine antigen expression can induce significant immune responses that are sustained for at least 1 year in the majority of antigen-naive subjects. The concept of using bacteria-derived plasmid DNA to deliver vaccine antigens has many attractive features, including ease and flexibility of construction, scalable manufacturing capacity, stability, intracellular production of vaccine antigen, transient expression, no induction of antivector immunity, induction of a balanced 
CD4
+ and CD8 + T cell response as well as of antibody, and lack of significant local or systemic reactogenicity. The broad immunogenicity of the VRC HIV-1 DNA candidate vaccine probably reflects a combination of factors, including optimization of vector design, manufacturing methods, delivery, sample processing, and immunological end-point measurements.
A notable feature of the immunogenicity analysis was the response to Env antigens relative to Gag, Pol, and Nef. The dominant antigenicity of Env was observed for both antibody and T cell responses, with EnvA peptides eliciting the greatest T cell responses and EnvC binding the most vaccine-induced antibody. All the genes encoding the vaccine antigens were codon modified to improve expression. The Env constructs received additional modification to remove the cleavage site, the fusion peptide of gp41, a region of the interspace between the 2 gp41 heptad repeats, and the cytoplasmic domain [3] , but there is no indication that these changes were responsible for liberating additional T cell epitopes. The gag/pol/nef construct was designed to remove the frame shift, resulting in improved expression of Pol and Nef, at the expense of 66 aa from the carboxy-terminus of Gag [18] . This construct was immunogenic in preclinical testing and exhibited strong protein expression in vitro [4] . Here, the Gag, Pol, and Nef antigens elicited only a modest induction of CD4 + T cell responses despite representing 50% of the plasmid mixture by weight. It is not known why the induction of Gag-, Pol-, and Nef-specific responses were lower than Env-specific responses, but there are several possible explanations for increased Env immunogenicity. First, since Env is a membrane glycoprotein, its intracellular trafficking and mode of antigen presentation differs from those of the internal viral proteins. Second, Gag, Pol, and Nef are not glycosylated, are synthesized in the cytoplasm, and localize to a subcellular compartment different from that of Env. Therefore, it is possible that the steps involved in antigen processing and the kinetics of antigen presentation may differ. Finally, our experiments in animal models indicate that Env contains more CD4 + T cell epitopes than does Gag or other proteins [19] . Thus, the increased immunogenicity of Env is potentially an intrinsic property of the expressed antigen.
Antibody responses induced by this 4-plasmid combination vaccine were detected by IP-Western blotting and research ELISA for vaccine-specific antigens as well as by commercial ELISA and Western blotting for native viral proteins (table 2) . Analysis of neutralization did not reveal significant activity. On the basis of animal studies, high levels of binding antibody and neutralizing activity are not anticipated after DNA immunization alone but can be achieved after subsequent boosting with replication-defective recombinant adenovirus vectors [20] . The induction of measurable antibody to clades A, B, and C Env proteins with DNA alone in humans is encouraging and suggests that DNA vaccination is a viable strategy for priming both cellular and humoral responses. Whether the response to all the Env proteins indicates cross-reactivity between clades or between clade-specific antibodies is not known. As multivalent vaccines become more immunogenic and clinical evaluation expands, the complexity of interpreting routine commercial diagnostic tests will increase. Alternative approaches to serological diagnosis, such as gene-based diagnostic approaches, will be needed in the future.
This DNA vaccine consistently induced T cell responses. Envspecific CD4 + T cell responses were present in nearly all subjects. Detection of this response may be attributed to the development of a highly sensitive flow cytometry-based assay that detects IFN-g and/or IL-2 on the same channel. Other studies have shown that most of the CD4 + T cell response can be captured by the combination of these 2 cytokines [21, 22] ; if IFN-g alone is used as the end point, a portion of the CD4 + T cell response is missed. CD8 + T cells are key effectors for clearing virus-infected cells [23] and have been associated with control of lentivirus replication in both nonhuman primates (NHPs) and humans [24] [25] [26] [27] [28] [29] [30] [31] [32] . Twelve (34%) of the 35 vaccine recipients who received the 4-mg or 8-mg doses had detectable HIV Env-specific CD8 + T cell responses at week 12. The magnitude of positive responses ranged from just above background to 0.65% of total CD8 + T cells. When detected, the magnitude of the CD8 + T cell response is comparable to that seen in NHP studies of similar vaccines, although typically CD8 + T cell responses can be detected in 100% of the animals [33, 34] . An interesting feature of the T cell response was that, over the course of a year, a higher frequency of EnvA-specific CD4 + and CD8 + T cells made IL-2 only. Reports that show that IFN-gproducing CD4
+ T cells are not long lived [35] and that IL-2-producing CD8 + T cells have a greater proliferative capacity in HIV-1-infected patients with nonprogressive disease [36] suggest that these IL-2-producing T cells may have the capacity for expansion after subsequent antigen exposure.
Demonstrating the safety and immunogenicity of a multigene, multiclade HIV DNA vaccine is an important step in the development of a globally relevant vaccination strategy. The capacity to make precise measurements of vaccine-induced T cell responses will improve the chances of defining correlates of immune protection in future trials. 
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